BioNTech says vaccine approval possible in mid-Dec under ideal conditions

FRANKFURT, Nov 18 (Reuters) - U.S. and European regulators could approve Pfizer and BioNTech’s experimental COVID-19 vaccine as early as mid-December, the German firm’s chief executive said on Wednesday, following the release of positive trial results.

Speaking to Reuters TV, Chief Executive Ugur Sahin said if all goes well, the U.S. Food and Drug Administration could grant emergency-use approval towards the end of the first half of December or early in the second half.

Conditional approval in the European Union could be achieved in the second half of December, he added.

“It will depend on the requests that we will receive and whether all the conditions are met.” (Reporting by Ludwig Burger, Patricia Weiss and Tilman Blasshofer; Editing by Jan Harvey)


Reuters Breakingviews is the world's leading source of agenda-setting financial insight. As the Reuters brand for financial commentary, we dissect the big business and economic stories as they break around the world every day. A global team of about 30 correspondents in New York, London, Hong Kong and other major cities provides expert analysis in real time.

Sign up for a free trial of our full service at and follow us on Twitter @Breakingviews and at All opinions expressed are those of the authors.